Shionogi Implements Stibo Systems MDM Solution - Yahoo Finance

Shionogi Implements Stibo Systems MDM Solution  Yahoo Finance

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program  Fierce Biotech

Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech

Bioversys, Shionogi in CHF529M lung infection collaboration  BioWorld MedTech

Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology

Shionogi awarded $375m from HHS for preventative Covid-19 injectable  Pharmaceutical Technology

Shionogi & Co., Ltd. Implements Stibo Systems MDM Solution - MarketScreener

Shionogi & Co., Ltd. Implements Stibo Systems MDM Solution  MarketScreener

Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum

Shionogi puts up to $600m behind BioVersys antibiotics  pharmaphorum

BioVersys and Shionogi Partner to Develop Ansamycin Antibiotics for Bacterial Infections - geneon...

BioVersys and Shionogi Partner to Develop Ansamycin Antibiotics for Bacterial Infections  geneonline.com

Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma

Shionogi strikes research and option deal with BioVersys for antibacterial assets  FirstWord Pharma

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion  Reuters

Shionogi Initiates First-Ever Human Study Testing Therapy for Ultra-Rare Jordan Syndrome - Neurol...

Shionogi Initiates First-Ever Human Study Testing Therapy for Ultra-Rare Jordan Syndrome  NeurologyLive

Shionogi Expands COVID-19 Drug Use to Younger Patients - TipRanks

Shionogi Expands COVID-19 Drug Use to Younger Patients  TipRanks

Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter

Shionogi pushes 2030 vision forward with $1 billion acquisition  The Pharma Letter

Action to Implement Management that is Conscious of Cost of Capital and Stock Price - Shionogi Inc.

Action to Implement Management that is Conscious of Cost of Capital and Stock Price  Shionogi Inc.

Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum

Shionogi aims to buy tobacco giant's pharma unit for $1bn  pharmaphorum

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults  Fierce Biotech

Shionogi Announces Treasury Shares Disposal for Compensation Plan - TipRanks

Shionogi Announces Treasury Shares Disposal for Compensation Plan  TipRanks

Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech

Shionogi to acquire Japan Tobacco pharma companies for $1.1B  BioWorld MedTech

Shionogi Completes Tender Offer for Torii Pharmaceutical Shares - TipRanks

Shionogi Completes Tender Offer for Torii Pharmaceutical Shares  TipRanks

Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch

Swiss firm BioVersys signs deal with Shionogi for antibiotics research  SWI swissinfo.ch

Shionogi To Acquire Torii Pharma Through $1.1B Tender Offer - Law360

Shionogi To Acquire Torii Pharma Through $1.1B Tender Offer  Law360

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - Business ...

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan  Business Wire

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations  Business Wire

BioVersys Partners with Shionogi for NTM Clinical Candidate Development - TipRanks

BioVersys Partners with Shionogi for NTM Clinical Candidate Development  TipRanks

Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B - Seeking Alpha

Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B  Seeking Alpha

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder  Yahoo Finance

Development of a Manufacturing Process for S-892216 Part I: A Novel Method for Constructing a Mul...

Development of a Manufacturing Process for S-892216 Part I: A Novel Method for Constructing a Multi-Substituted Barbiturate Skeleton for Scalable Synthesis  ACS Publications

Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance - Contagion Live

Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance  Contagion Live

Bristol Myers’ $40B US investment; Shionogi to buy Japanese drugmaker - Endpoints News

Bristol Myers’ $40B US investment; Shionogi to buy Japanese drugmaker  Endpoints News

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants  BioWorld MedTech

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases - BioSpect...

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases  BioSpectrum Asia

Shionogi & Co. Reports Fiscal Year 2024 Financial Results with Positive Outlook - TipRanks

Shionogi & Co. Reports Fiscal Year 2024 Financial Results with Positive Outlook  TipRanks

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission  Reuters

Shionogi Submits NDA for COVID-19 Antiviral Ensitrelvir to FDA - TipRanks

Shionogi Submits NDA for COVID-19 Antiviral Ensitrelvir to FDA  TipRanks

Clinigen and Shionogi formalize licensing pact for cefiderocol - The Pharma Letter

Clinigen and Shionogi formalize licensing pact for cefiderocol  The Pharma Letter

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants - BioWorld MedTech

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants  BioWorld MedTech

Accelerating drug discovery with AI innovation - SAS Institute

Accelerating drug discovery with AI innovation  SAS Institute

Shionogi’s $1.1 Billion Torii Acquisition: A Strategic Play for Growth in Renal and Dermatology M...

Shionogi’s $1.1 Billion Torii Acquisition: A Strategic Play for Growth in Renal and Dermatology Markets  AInvest

Shionogi Reports Mixed Financial Performance for Q3 FY2024 - TipRanks

Shionogi Reports Mixed Financial Performance for Q3 FY2024  TipRanks

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal - Nikkei Asia

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal  Nikkei Asia

Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with GSK, Shionogi, ...

Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with GSK, Shionogi, and Eli Lilly Leading  geneonline.com

Shionogi Acquires Full Ownership of Joint Ventures - TipRanks

Shionogi Acquires Full Ownership of Joint Ventures  TipRanks

A Pill to Prevent COVID-19 Shows Promise - Time Magazine

A Pill to Prevent COVID-19 Shows Promise  Time Magazine

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone ...

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone  CalMatters

Shionogi's RSV antiviral shows promise in hVIVO trial - MSN

Shionogi's RSV antiviral shows promise in hVIVO trial  MSN

Shionogi presents pivotal ensitrelvir fumaric acid Phase 3 data and exploratory long COVID data -...

Shionogi presents pivotal ensitrelvir fumaric acid Phase 3 data and exploratory long COVID data  European AIDS Treatment Group

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19...

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis  Business Wire

Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - Eura...

Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO  Euractiv

Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study - FirstWord Pharma

Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study  FirstWord Pharma

Japan's Shionogi-Torii Pharmaceutical merger conditionally cleared by JFTC - MLex

Japan's Shionogi-Torii Pharmaceutical merger conditionally cleared by JFTC  MLex

Shionogi Completes Tender Offer for Torii Pharmaceutical, Acquiring 39% Stake - MarketScreener

Shionogi Completes Tender Offer for Torii Pharmaceutical, Acquiring 39% Stake  MarketScreener

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya - B...

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya  BioSpectrum Asia

APAC Healthcare Weekly (July 6)- Shionogi, Simcere, Wuxi XDC, Sino Bio, Apollo Hosp, Torrent Phar...

APAC Healthcare Weekly (July 6)- Shionogi, Simcere, Wuxi XDC, Sino Bio, Apollo Hosp, Torrent Pharma  Smartkarma

Shionogi & Co., Ltd. agreed to acquire Pharmaceutical business of Japan Tobacco Inc from Japan To...

Shionogi & Co., Ltd. agreed to acquire Pharmaceutical business of Japan Tobacco Inc from Japan Tobacco Inc..  MarketScreener

Corrected: Vilya raises $21M in Series A extension; Shionogi to open research center in San Diego...

Corrected: Vilya raises $21M in Series A extension; Shionogi to open research center in San Diego  Endpoints News

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan  GlobeNewswire

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand  BioSpectrum Asia

Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter

Shionogi’s ensitrelvir prevents symptomatic COVID-19  The Pharma Letter

Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...

Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024  Yahoo Finance

Shionogi & Co: To Launch Tender Offer For Torii Pharmaceutical Shares At 6,350 Yen Per Share - Ma...

Shionogi & Co: To Launch Tender Offer For Torii Pharmaceutical Shares At 6,350 Yen Per Share  MarketScreener

Ensitrelvir Effective as Oral Antiviral for Postexposure Prophylaxis Against COVID-19 - Pharmacy ...

Ensitrelvir Effective as Oral Antiviral for Postexposure Prophylaxis Against COVID-19  Pharmacy Times

First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Develop...

First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Development of Synthetic Methods to Prepare Baloxavir Marboxil Intermediates  ACS Publications

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Yahoo

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission  Yahoo

Antibiotics, an important but tricky business, says Shionogi CEO - Euractiv

Antibiotics, an important but tricky business, says Shionogi CEO  Euractiv

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculou...

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate  The Manila Times

Top Japanese firms steer USD1.1bn Japan pharma takeover - Law.asia

Top Japanese firms steer USD1.1bn Japan pharma takeover  Law.asia

Global study shows cefiderocol’s success in treating resistant infections - European Pharmaceutic...

Global study shows cefiderocol’s success in treating resistant infections  European Pharmaceutical Manufacturer

Cilcare Secures Funding to Advance Clinical Trials for Cochlear Synaptopathy Treatment - The Hear...

Cilcare Secures Funding to Advance Clinical Trials for Cochlear Synaptopathy Treatment  The Hearing Review

Shionogi's RSV antiviral shows promise in hVIVO trial - Investing.com

Shionogi's RSV antiviral shows promise in hVIVO trial  Investing.com

Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city re...

Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city resilient to infectious diseases  BioSpectrum Asia

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOU...

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE  boerse.de

Chronic Refractory Cough Market Size to Reach USD 14.9 Billion by 2035, Impelled by Increasing Re...

Chronic Refractory Cough Market Size to Reach USD 14.9 Billion by 2035, Impelled by Increasing Research & Development Activities  BioSpace

Masahiro Fujita - Shionogi Inc.

Masahiro Fujita  Shionogi Inc.

David Benadon｜ 塩野義製薬 - Shionogi Inc.

David Benadon｜ 塩野義製薬  Shionogi Inc.

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19  National Institutes of Health (NIH) | (.gov)

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value  Shionogi Inc.

Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 - Shionogi Inc.

Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬  Shionogi Inc.

Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology

Shionogi to acquire Qpex Biopharma for $140m  Pharmaceutical Technology

Margaret Borys - Shionogi Inc.

Margaret Borys  Shionogi Inc.

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and Academia to Tackle Infectious Diseases  Shionogi Inc.

Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.

Notice of Head Office Relocation｜ 塩野義製薬  Shionogi Inc.

Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace

Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline  BioSpace

History - Shionogi Inc.

History  Shionogi Inc.

Nathan McCutcheon - Shionogi Inc.

Nathan McCutcheon  Shionogi Inc.

Chris Klein - Shionogi Inc.

Chris Klein  Shionogi Inc.

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOU...

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE  Ariva

Tadashi Hara - Shionogi Inc.

Tadashi Hara  Shionogi Inc.

Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego - Genetic Engineering and Biotechnology...

Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego  Genetic Engineering and Biotechnology News

Message from Top Management - Shionogi Inc.

Message from Top Management  Shionogi Inc.

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation H...

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals  GSK

Japan to grant emergency approval to Shinogi COVID-19 drug - Reuters

Japan to grant emergency approval to Shinogi COVID-19 drug  Reuters

After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech

After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M  Fierce Biotech

Our promise - Shionogi Inc.

Our promise  Shionogi Inc.

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacteri...

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries  Clinton Health Access Initiative

Financial Highlights - Shionogi Inc.

Financial Highlights  Shionogi Inc.

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial  Reuters

Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - biocentury.com

Clinical Report: Shionogi mulls next steps after underwhelming obesity readout  biocentury.com

Investigator-Initiated Research - Shionogi Inc.

Investigator-Initiated Research  Shionogi Inc.

Maze lands new partner for Pompe drug, after Sanofi pact came apart - BioPharma Dive

Maze lands new partner for Pompe drug, after Sanofi pact came apart  BioPharma Dive

Shionogi sinks in Tokyo trade after panel again delays COVID pill approval - Reuters

Shionogi sinks in Tokyo trade after panel again delays COVID pill approval  Reuters

Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia

Japan's Shionogi seeks China approval for superbug-fighting antibiotic  Nikkei Asia